GlassScriptPhysician profile
Grisell Ramirez
NPI 1285987941
$8,287.39
in general payments reported to CMS, 2019-2025
25 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $425 · 2022: $1,822 · 2023: $1,756 · 2024: $2,106 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,963 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,963.06 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,906.68 | 2022-2025 | |
| Amgen INC. | $1,332.02 | 2021-2025 | Tavneos, Krystexxa, Enbrel |
| Janssen Biotech, INC. | $1,099.10 | 2021-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $640.30 | 2021-2025 | Benlysta |
| Ucb, INC. | $565.64 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $498.10 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $454.37 | 2022-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $345.60 | 2021-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $233.63 | 2021-2024 | Tremfya |
| Aurinia Pharma U.S., INC. | $224.12 | 2022-2025 | Lupkynis |
| Pfizer INC. | $208.70 | 2021-2023 | |
| Lilly USA, LLC | $208.18 | 2021-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.40 | 2024-2025 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $51.92 | 2024-2025 | Orencia |
| Horizon Therapeutics Plc | $49.22 | 2023 | Krystexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $48.31 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $47.89 | 2023-2024 | Strensiq |
| Radius Health, INC. | $46.52 | 2024 | |
| Mallinckrodt Hospital Products INC. | $34.55 | 2021-2022 | |
| Organon LLC | $31.47 | 2024 | |
| Fresenius Kabi USA, LLC | $29.35 | 2023 | Idacio |
| Octapharma USA, INC. | $27.90 | 2024 | Octagam Immune Globulin (Human) |
| Scilex Pharmaceuticals INC. | $23.98 | 2024 | |
| Incyte Corporation | $22.68 | 2025 | Opzelura |
| Genentech USA, INC. | $16.76 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grisell Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.